Volume 57, Issue 2 pp. 177-182
Report

Treatment of severe drug reactions by hemodialysis

Rokea A. el-Azhary MD, PhD

Corresponding Author

Rokea A. el-Azhary MD, PhD

Department of Dermatology, Mayo Clinic, Rochester, MN, USA

Correspondence

Rokea A. el-Azhary, md, phd

Department of Dermatology

Mayo Clinic

200 First St SW

Rochester, MN 55905

USA

E-mail: [email protected]

Search for more papers by this author
Michael Z. Wang MD

Michael Z. Wang MD

Department of Dermatology, Mayo Clinic, Rochester, MN, USA

Search for more papers by this author
Ashley B. Wentworth MD

Ashley B. Wentworth MD

Department of Dermatology, Mayo Clinic, Rochester, MN, USA

Search for more papers by this author
LaTonya J. Hickson MD

LaTonya J. Hickson MD

Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA

Search for more papers by this author
First published: 22 November 2017
Citations: 7
Funding: Dr. Hickson is supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (K23 DK109134).
Conflicts of interest: none.
IRB status: Exempt.

Abstract

Background

Extracorporeal treatments such as hemodialysis and plasma exchange are lifesaving measures in the treatment of drug poisoning. This treatment method generally is not used for severe cutaneous and systemic drug reactions.

Methods

Here, we describe three cases wherein hemodialysis therapy was instrumental in reversing the adverse drug reaction.

Results

In the cases of severe cutaneous drug reactions reviewed, patients presented with linear immunoglobulin A bullous dermatosis, acute generalized exanthematous pustulosis, and toxic epidermal necrolysis. Salvage treatment with hemodialysis therapy drastically influenced the course of disease, resulting in remission.

Conclusions

This novel and highly effective treatment option is not considered in current algorithms for adverse drug reactions. Hence, in addition to the rarity of these reactions, the main limitation of the study is the small number of patients. Hemodialysis can substantially alter the prognosis and, in some cases, be a lifesaving treatment for patients with severe adverse cutaneous drug reaction associated with systemic toxicity.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.